Pooled RECORD data "confirm Xarelto better than Lovenox"
Results from a pre-specified pooled analysis of the RECORD trial program confirmed that Bayer's oral anticoagulant Xarelto (rivaroxaban) once-daily was superior to enoxaparin-based treatment regimens for the prevention of venous thromboembolism after total knee or hip replacement surgery with low rates of major bleeding that were not statistically different from the comparator.
The German drug major reported pooled results from all four RECORD trials, which involved over 12,500 patients, at the 50th annual meeting of the American Society of Hematology in San Francisco.
At all time points assessed, patients on Xarelto showed a statistically-significant reduction of more than 50% in the composite primary efficacy endpoint compared to those treated with the market leader, Sanofi-Aventis' Lovenox (enoxaparin).
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze